Overall survival and post-progression survival are potent endpoint in phase III trials of second/third-line chemotherapy for advanced or recurrent epithelial ovarian cancer

Purpose: A growing number of treatment options and active compounds in treatments have led to better outcomes for patients with advanced or recurrent epithelial ovarian cancer. We examined the association between progression-free survival (PFS), post-progression survival (PPS) and overall survival (...

Descripción completa

Detalles Bibliográficos
Autores principales: Shimokawa, Mototsugu, Kogawa, Takahiro, Shimada, Takako, Saito, Toshiaki, Kumagai, Hozumi, Ohki, Masafumi, Kaku, Tsunehisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5868151/
https://www.ncbi.nlm.nih.gov/pubmed/29581765
http://dx.doi.org/10.7150/jca.17664

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5868151/
https://www.ncbi.nlm.nih.gov/pubmed/29581765
http://dx.doi.org/10.7150/jca.17664

Ejemplares similares